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Introduction
Cancer is one of the most important issues of 
general health and economic concern throughout the 
world (Ferlayet al., 2007). Breast cancer is the most 
common type of cancer amongst women, whether in 
developed or developing countries. According to World 
Health Organization (WHO) approximately 508,000 
individuals died of breast cancer in 2011. Although this 
disease is attributed to the developed countries, about 
50% of theses cancer cases and 58% of cancer deaths 
had occurred in the developing countries (GLOBOCAN, 
2012 ). Prevalence of this disease increases up to 1 to 
2% per year in the developed countries, and up to 5% 
per year in the underdeveloped ones. In 2011, around 
2.6 million people survived breast cancer in the United 
States and about 39,520 women lost their lives to this 
disease (Kolahdoozan et al., 2010). Prevalence of breast 
cancer has had a yearly increase in Iran and nowadays, it 
is recognized as the most common type of cancer among 
Iranian women. According to the latest statistics presented 
by the Ministry of Healthcare and Medical Education, 27 
out of every 100,000 women have been diagnosed with 
breast cancer. This disease is considered a very serious 
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one in Iran, since breast cancer affects Iranian women 
a decade sooner than women from western countries 
(Kolahdoozan et al., 2010). During the recent years, 
survival rates of the disease have increased as a result of 
proper screening programs and advances in adjuvants to 
surgery. Therefore, there has been tremendous growth in 
the number of cancer survivors needing follow-ups after 
treatment (NCCN, 2013). The main purpose of follow-up 
plan is early detection of recurrences in patients who had 
received standard treatments. Occurrence of metastasis 
can lead to a shorter life span and decreased quality of life 
in cancer patients. Most recurrence cases are witnessed 
within the first two to five years of follow ups (Ghohari 
et al., 2006; Moschetti et al., 2016). Therefore, in order 
to detect metastasis and recurrences at an early stage, 
outpatient follow-ups are done along with additional 
tests, depending on the clinic or hospital’s guidelines 
(Margenthaler et al., 2014).
There are standard follow-up guidelines specific to 
breast cancer patients. The National Comprehensive 
Cancer Network (NCCN) recommended follow-up plan 
is not classified based on cancer stage, however, they are 
performed for patients with stages 0 – III breast cancer 
(Margenthaler et al., 2012; Margenthaler et al., 2014).
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Despite the huge number of cancer patients in Iran, 
including breast cancer patients, a good level of success 
has been achieved in treating the disease due to proper 
screening systems and increased awareness of society; this 
increases survival rates and thus the number of individuals 
needing long years of follow-ups (at least five years) 
would increase (Daroudi et al., 2015). Currently, there are 
various follow-up strategies implemented in Iran, which 
are usually dependent on clinic policies and agreements 
among the clinic’s oncologists. These strategies include the 
intensive and standard follow-up models recommended by 
NCCN’s guidelines. As our searches show, there hasn’t 
been a study in Iran with regards to cost-effectiveness of 
Intensive vs. Standard follow-up strategies, yet. In this 
study, in addition to determining cost-effectiveness of 
the mentioned models, the researchers aimed to evaluate 
the direct costs of prescribed tests and measures from the 
payer’s perspective using economic evaluation techniques; 
by determining a cost-effective model as the most 
convenient strategy. Through this, we might be able to take 
a step toward presenting a general guide for prescription 
of suitable tests. This consequently saves huge amounts 
of financial resources and may lead to imposition of less 
financial burden on the healthcare system.
Materials and Methods
The guidelines of the National Comprehensive Cancer 
Network (NCCN) recommend obtaining patient history, 
performing physical examinations every 3-6 months 
as well as annual mammography, chest radiography, 
blood tests, abdominal ultrasound, breast ultrasound, 
bone mineral density test, and pelvic ultrasound for 
those patients receiving letrazole and tamoxifen for two 
years and then after, if there is no recurrence, obtaining 
patient history and physical examination every 6-12 
months and annual mammography, blood tests and bone 
scan is suggested. They have also recommend annual 
examinations specifically for women on Tamoxifen, 
and annual bone mineral density tests for patients who 
take aromatase inhibitors such as Letrazole; additional 
diagnostic tests should only be performed when an 
anomaly is witnessed in physical examinations, medical 
history or the mammograms (NCCN, 2013). On the other 
hand, the standard follow-up model merely consists of 3-6 
months’ doctor visits and annual mammography for the 
first two years of follow up and if there is no recurrence, 
obtaining patient history and physical examination every 
6-12 months and annual mammography (NCCN, 2013). 
Since the follow-up protocol of Imam Reza specialized 
clinic of Shiraz is similar to NCCN’s intensive follow-up 
model to a high degree, thus patients in this clinic were 
selected as the intensive group; and the patients at the 
Cancer Institute of Tehran’s Imam Khomeini hospital 
were selected as the standard group, because of the high 
resemblance between NCCN’s standard follow-up plan 
and this clinic’s follow-up protocols.
This cross-sectional study was an economic evaluation 
research among breast cancer patients who had received 
full treatment and at least five years of follow-ups 
from the mentioned clinics. Inclusion criteria included 
non-metastatic cancer in one or both breasts at the 
time of diagnosis, completion of surgical treatment, 
chemotherapy, radiation therapy and hormone therapy, and 
continuance of follow-ups until the year 2014. Exclusion 
criteria were incomplete treatment and lack of success in 
finding patients through phone calls.
When population variance and the variable’s 
probability of success are unknown and we are not 
able to use statistical formulas to estimate sample size, 
maximum sample size is determined by using Morgan’s 
table. Therefore, our study’s population was determined 
as about 75,000 individuals and sample size was estimated 
at 382 individuals in each group (764 patients in total). 
The reason why this sample size was selected was due to 
that fact that our population size was unknown and we 
only had access to file numbers and types of cancer in the 
clinics’ registry systems. Therefore, only after reading the 
file contents we could determine the non-occurrence of 
metastasis at the time of diagnosis, which was among the 
study’s inclusion criteria.
Using the data collection form, the demographic 
information of survivors and information regarding 
disease, treatment and number and types of diagnostic tests 
were extracted from the case records of treated patients 
under surveillance from 2008 to 2014. Because of the 
minimum 5-year follow-up criterion, the case records 
of patients who were diagnosed in the years 2007 to 
2009 were assigned numbers and then 382 samples were 
randomly selected for each group. Based on the prognostic 
factors recorded in the patient’s records, such as Estrogen 
receptors (ERs), Progesterone receptors (PRs) and human 
epidermal growth factor receptor 2 (HER2), the survivors 
were divided into four groups of A, B, C and D, so that 
their follow-up process could be evaluated more accurately 
based on occurrence risk of metastasis, which would make 
them somewhat synchronized. Group A were ER and PR 
positive and HER2 negative; group B were ER and PR 
positive, as well as HER2 positive; group C were ER and 
PR negative and HER2 positive; and group D were both 
ER and PR negative and HER2 negative.
The time variable was determined as from the time 
of treatment completion and the first follow-up visit until 
observation of the first incident, whether it be recurrence 
of cancer in the breasts or metastasis in other parts of the 
body.
To compare cost-effectiveness of the standard and 
intensive follow-up models, we used a decision tree model 
along with the indicator of case detection or detection of 
recurrences and metastasis. First, we calculated expected 
costs and expected case detections based on this model, 
and then reached the incremental cost-effectiveness ratio. 
The incremental cost-effectiveness ratio (ICER) is defined 
as the difference between expected costs and expected case 
detections; it is used to increase research accuracy and 
reduce unreliability of sensitivity analysis. The decision 
tree model is presented in Figure 1.
The decision tree shows the survivors’ final state across 
2 conditions including relapse (metastasis) and no relapse 
(no metastasis). In the relapse condition, the indicator of 
case detection is presented based on the two states of by 
tests (detection of metastasis by diagnostic tests before 
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information from each section of the data collection form 
into the SPSS software package for Windows, Version 19 
(SPSS Inc., Chicago, USA). Descriptive tests were used 
to estimate relative and absolute frequency of data based 
on both follow-up models, and the Mann-Whitney test 
determined the significant cost differences. This study’s 
event was determined as the period until occurrence of 
the first event, meaning that a recurrence or metastasis; 
values less than or equal to 5% were considered significant 
statistically. For economic analyses such as analysis of the 
cost-effectiveness diagram, calculation of the incremental 
cost-effectiveness ratio, drawing of the Tornado Diagram 
and sensitivity analysis of certainty, we used the Treeage 
Pro 2012 software (Treeage Software Inc., Williamstown, 
MA, USA).
Results
Of the 764 survivors in our study (382 individuals 
in each group), 91.4% were married, 76.7% were above 
40 years old and 63.6% were residents of urban areas; 
regarding types of insurance, the highest frequency 
(39.1%) pertained to patients under social security 
insurance and 79.4% of the patients didn’t have any kind 
of extra insurance (supplementary). Most of the survivors 
(42.9%) were at the stage 3 of the disease, and 59.4% 
of them had been placed under the intensive follow-up 
plans. Comparing tumor size among patients revealed that 
66.9% of them had 2-5 cm tumors, 73.0% of which were 
placed under the intensive follow-up plan. Furthermore, 
appearance of clinical signs) and by physician (diagnosis 
of metastasis by the physician after appearance of clinical 
signs); in this study, the by test state is selected as the case 
detection indicator (effectiveness criterion). In this study, 
we aimed to see if the numerous diagnostic tests of the 
intensive follow-up model had been effective enough in 
early detection of metastasis and recurrences, or they just 
simply imposed additional costs on patients without really 
having the ability to detect recurrences and metastasis on 
time. To this end, we studied physician notes regarding 
each patient’s general condition and the results of each 
follow-up visit recorded in the records.
In this research, costs are calculated from the 
perspective of the payer (patients and insurance 
companies); in this regard, we calculated the direct 
costs of follow-ups for breast cancer patients, including 
costs of each diagnostic and lab test (mammography, 
blood test, chest radiography, abdominal ultrasound, 
pelvic ultrasound, breast ultrasound, and bone mineral 
density) over a year using the private fees published by 
the Ministry of Healthcare and Medical Education, and 
eventually reached at the total follow-up cost for each 
patient during the follow-up period 2008–2014. Since we 
only had access to patient records in this study, only the 
direct medical costs was entered into our calculations and 
indirect costs or direct non-medical costs weren’t used, 
because they weren’t included in the records and there 
were errors in the stated costs for previous years. Also, 
since both clinics were public and had similar number of 
visits at the same cost, we disregarded all costs relating 
to this variable.
Because the follow-ups were done during the period 
of 2008 to 2014, all costs were converted to values of the 
study year (2014), using the inflation rates reported by 
the Central Bank of Iran; therefore, since past data were 
converted to present values, there was no need to use 
discount rates in this study.
For analysis of demographic data, we entered the 
Figure 1. The Decision tree for Along with the Indicator 
of Case Detection or Detection of Recurrences and 
Metastasis. Group A: Estrogen Receptor (ER) and 
Progesterone Receptor (PR) positive and epidermal 
growth factor receptor 2 (HER2) negative, Group B: ER 
and PR positive and HER2 positive, Group C were ER 
and PR negative and HER2 positive, Group D: both ER 
and PR negative and HER2 negative
Figure 2. Cost-Effectiveness Analysis of the Standard 
and Intensive Follow-up Models for Breast Cancer 
Survivors
Figure 3. Tornado Analysis Relating Sensitivity of the 
Intensive and Standard Follow-up Models
Nahid Hatam et al
Asian Pacific Journal of Cancer Prevention, Vol 175312
34.3% of the patients had 1-3 involved lymph nodes, of 
which 39% were placed in the standard follow-up group. 
According to study findings, 68.2% of the patients were 
in the estrogen and progesterone receptor positive groups 
and 58.0% were positive for HER2. Therefore, 40.8% 
of the survivors belonged to group B (Table 1). Most of 
the survivors (61.5%) had had a mastectomy; 99.21% 
had been placed under chemotherapy and 91.6% had 
received radiation therapy. Among the studied patients, 
86.0% had never experienced treatment with herceptin. 
However, 34.3% of them had received hormone therapy 
with letrazole and 30.7% had hormone therapy with 
tamoxifen in their treatment plan.
Of the 764 survivors in this study, 31.9% had occurrence 
of metastasis, out of which 35.1% were placed under the 
standard follow-up plan. Since the time of detection of 
recurrences or metastasis is of importance, we studied this 
indicator. Our findings revealed that metastasis has been 
diagnosed in the third year of follow-up for 45.3% of the 
patients, from which 47.3% received standard follow-up 
care. 75.9% of the patients with metastatic relapse had 
been diagnosed by physician based on clinical signs. Most 
of the patients with metastasis (37.9%) had metastatic 
bone involvement. Findings also revealed that up to year 
2014, 65.9% of the patients under the standard follow-up 
plan and 70.9% of the patients under intensive follow-
up had survived without any recurrences. Among the 
mentioned variables, only the variable of detection method 
for recurrence and metastasis was statistically significant 
for the two follow-up groups; there were more early 
detections (detection of metastasis by diagnostic tests 
before the appearance of clinical signs) in the intensive 
group (p<0.001). On the other hand, 65 (17.0%) and 87 
(22.0%) of intensive and standard treatment groups were 
died by the end of the study, respectively. 
According to table 1 with regards to cost analysis, 
it was revealed that in the intensive follow-up group, 
the highest total follow-up cost belonged to group B 
(ER and PR positive and HER2 positive) with total cost 
of $ 62,345.05 US dollars, and the highest total cost in 
the standard follow-up group pertained to group A (ER 
and PR positive and HER2 negative) with total cost of 
$14,605.00; overall, the intensive follow-up model had 
a 2.7 times higher total cost ($1,190.1) than the standard 
model ($43,150.0). Highest mean follow-up cost per 
patient belonged to group D (ER and PR negative and 
HER2 negative) in the intensive group ($40.6), and group 
A in the standard group ($120.7). The mean follow-up 
cost difference was statistically significant between the 
two groups of intensive follow-up ($311.53) and standard 
follow-up ($112.9); the intensive group had a higher mean 
cost (p<0.001). Although, the mean costs of all four group 
were quite close in the standard group.
Discussion
The decision tree results presented in Table 2 
shows expected case detection rate as 0.137 and 0.018 
and expected costs as $24,494.6 and $6,859.3 for 
intensive and standard follow-up models, respectively. 
The cost-effectiveness analysis diagram (Figures 2, 3) 
indicates that comparing to the standard follow-up model, 
the intensive model increases costs and effectiveness by 
$17,635.3 and 0.119, respectively. Thus, for the purposes 
of decision-making, we calculated the incremental 
cost-effectiveness ratio (ICER) and compared it with its 
threshold. The calculated ICER indicates that for each 
unit of increase in effectiveness, the intensive follow-up 
model would increase costs by $148,196.2, comparing to 
the standard model.
Intensive Follow-up Group Standard Follow-up Group
Costs ($US) Costs ($US)
Group Number of patients (%) Total Per patient Number of patients (%) Total Per patient
A 91 (23.8) 27,526 302.4 121 (31.7) 14,605 120.7
B 185 (48.5) 62,348 337 127 (33.2) 13,072 103
C 65 (17) 16,690 256.7 71 (18.6) 8,128 114.4
D 41 (10.7) 12,443 407 63 (16.5) 7,345 118.5
Total 382 (100) 119,007 - 382 (100) 43,150 -
Table 1. Relative and Absolute Frequency of Breast Cancer Survivors Classified Based on ER, PR and HER2 in the 
Intensive and Standard Follow-Up Models; and also Follow-Up Costs Based on Private Fees (US Dollars) Divided 
by the Follow-Up Groups 2008-2014
Group A, ER and PR positive and HER2 negative; Group B, ER and PR positive and HER2 positive; Group C, ER and PR negative and HER2 
positive;  Group D, ER and PR negative and HER2 negative










Intensive 24,494.62 0.137 17,635.35 0.119 There is a need for 
comparison of ICER with the 
threshold value
Standard 6,859.27 0.018
Table 2. Results from the Decision Tree Model Regarding Intensive and Standard Follow-up Models Among the 
Breast Cancer Survivors of Imam Reza Clinic of Shiraz and Cancer Institute of Tehran during the Years 2008-2014
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We used World Health Organization’s (WHO) method 
to calculate the threshold value; therefore, if ICER was 
lower than three times Gross Domestic Product (GDP) 
per capita, the plan would be cost-effective (Koko et 
al., 2005).According to the World Bank’s report in 
2014, our country’s GDP per capita equaled to $5,442.9 
(Kolahdoozan et al., 2011). The threshold value is three 
times this amount, meaning $16,328.7 US dollars. 
Furthermore, since ICER was obtained as $148,196.2, 
an amount above the threshold ($16,328.7), therefore 
the intensive follow-up method is not cost-effective 
comparing to the standard model.
For the purposes of sensitivity analysis in this study, 
all variable values were increased by 20%; we drew the 
Tornado diagram based on this analysis. The Tornado 
diagram (Figure 3) reveals that study results had the 
highest sensitivity to cost increases in the intensive 
follow-up model (C intensive), and the lowest sensitivity 
to increases in the effectiveness of the standard follow-up 
model (E standard). Discussion
While there is talk regarding the limitations of 
healthcare budget in Iran, a developing country, it happens 
a lot that the scarce budget is wasted in follow-ups for no 
apparent reason, through unnecessary number of visits 
and unreasonable types of imaging such as MRIs and 
ultrasounds as well as various blood tests in each visit. 
These unnecessary tests result in imposing additional 
costs on patients as well as the totality of healthcare 
system (Baena et al., 2013). In recent years, the number of 
breast cancer survivors has increased as a result of proper 
screening plans and advances in adjuvants to surgery. 
When most breast cancer patients are diagnosed in early 
stages of the disease and have proper prognosis, there 
would be a need for many years of follow-ups, as well 
as huge amounts of healthcare resources. Therefore, it is 
important to discuss cost-effectiveness and the contents 
of these types of follow-ups (Kolahdoozan et al., 2010; 
Kimman et al., 2011; Van hezewijk et al., 2012). Economic 
evaluation compares the costs and outcomes of these 
interventions and plans for the purposes of proper resource 
allocation (Hatam et al., 2015).        
This study aimed to evaluate cost-effectiveness of the 
intensive follow-up model in comparison with the standard 
one, amongst breast cancer survivors. Findings revealed 
that the mean costs of intensive and standard follow-up 
models to be $112.9 and $311.5 US dollars, respectively, 
which was higher in the intensive group. This shows a 
significant difference (p<0.001). Meanwhile, the highest 
mean follow-up costs per patient belonged to group D 
($407.0) in the intensive group and group A ($120.7) in 
the standard group. Also, highest total follow-up costs 
pertained to group B ($62347.5) in the intensive group 
and group A ($14,605.00) in the standard group; overall, 
the total follow-up cost for the intensive group ($11,900.7) 
was approximately 2.7 times the total cost for the standard 
group ($143,150.0). Oltra et al., (2007) found mean 
follow-up costs per person to be €1,278 and €390 for the 
intensive and standard follow-up groups, respectively. 
Furthermore, they stated that the total follow-u costs as 
€24,567.0 in the standard group and €74,171.0 in the 
intensive group, which revealed that the follow-up costs 
was 3 times higher in the intensive model comparing to 
the standard one (Lauzier et al., 2013). Koko et al., (2005) 
confirmed the same results; in their study, the intensive 
model increased follow-up costs by 2.2 times (Rosselli 
Del Turco et al., 1994).
Lu et al., (2012), Margenthaler et al., (2014) and 
Kimman et al., (2007) all emphasized that a lower-intensity 
follow-up plan, aside from relieving the physicians of 
unnecessary burdens could lead to significant reduction of 
costs along with detection of metastases without any signs 
and recurrences in the same part of the body (Gohari et al., 
2006; Van hezewijk et al., 2012; Lu et al., 2012). Although 
in the present study the less intensive follow-up plan 
reduced the costs, but it wasn’t effective in the detection 
of recurrences and metastasis without clinical signs.
According to our results, case detection rates were 
0.137 and 0.018 for the intensive and standard groups, 
respectively. Considering the study findings, we can state 
that the intensive follow-up model had a higher number 
of early metastasis detections, which could be as a result 
of numerous diagnostic tests and visits to the specialists.
Since this study was the first one regarding 
cost-effectiveness of intensive vs. standard follow-up 
models for breast cancer survivors based on case detection, 
hence, we weren’t able to compare results with other 
studies. Nevertheless based on our results, the intensive 
follow-up model wasn’t cost-effective in comparison with 
the standard model; because the intensive model expected 
costs was $24,494.6 and case detection ratio of 0.138, 
while the standard model expected costs was $68,59.3 
and case detection of 0.018. Therefore, comparison of 
the incremental cost-effectiveness ratio with its threshold 
revealed that with each unit of increase in effectiveness, 
the intensive model would cause a $148,196.2 increase in 
costs, compared to the standard model. Now since ICER 
is above the threshold, we can state that the intensive 
follow-up model isn’t cost-effective in comparison with 
the standard one.
In this study, in order to evaluate accuracy of the 
ICER results, we did sensitivity analysis, which  enables 
us to determine the decisive parameters in the results of 
economic evaluation. Based on the results of the sensitivity 
analysis, which was performed with a 20% increase in 
all data, ICER had the highest sensitivity to the cost 
increases of the intensive model and the lowest sensitivity 
to increases in the effectiveness of the standard model. 
Subsequently, in this condition ICER would increase 
greatly in comparison to the initial value, therefore we 
would be able to comment on the cost-effectiveness of 
standard vs. intensive models with higher accuracy. On the 
other hand, ICER has low sensitivity to most parameters 
and this could increase generalizability of the results.
Toward generalization of this finding, we can extend 
this result to other follow-up clinics in our country, 
because they all use the same two follow-up strategies 
(Standard and Intensive) for breast cancer patients. 
However, we cannot positively extend this result to other 
countries because of the probable differences in costs 
and levels of coverage by their insurance organizations, 
patients’ ability to pay, incidence and prevalence of the 
disease and survival rates, clinical guidelines, and test fees 
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as well as system and maximum amounts of payment.
All in all, our results showed that the intensive 
follow-up model isn’t cost-effective in comparison 
with the standard model, since its ICER is above WHO 
announced threshold value (three times GDP per capita).
Therefore, based on the result from evaluation of 
cost-effectiveness, we recommend that oncologists use 
the standard follow-up model for survivors, rather than 
the intensive one.
Acknowledgment
This research was performed by Ms. Mina Vazirzadeh 
in partial fulfillment of the requirements for obtaining an 
MSc in Health Administration at Shiraz University of 
Medical Sciences. This article is the result of a research 
project (93-7370) approved by the Deputy of Research 
of the aforementioned university. Also, we thank the 
Research Consultation Center (RCC) at Shiraz University 
of Medical Sciences for their invaluable assistance in 
editing this article. 
Authors’ contribution to the manuscript
Nahid Hatam: Protocol/project management, Data 
management, Data analysis, Manuscript Writing and 
editing
Niloofar Ahmadloo: Patient management, Manuscript 
editing
Mina Vazirzadeh: Data management, Data collection, 
Data analysis, Manuscript Writing
Abdossaleh Jafari: Data management, Data analysis, 
Manuscript editing
Mehrdad Askarian: Protocol/project management, 
Data management, Data analysis, Manuscript Writing 
and editing
Compliance with Ethical Standards
Funding
 This study was funded by Shiraz University of Medical 
Sciences (grant number 93-7370). 
Conflict of Interest:  None to declare
Ethical approval 
This article does not contain any studies with human 
participants performed by any of the authors.
References
Baena J M, Ramirez P, Cortes C, et al (2013). Follow-up of 
long-term survivors of breast cancer in primary care versus 
specialist attention. Family practice, 30, 525-32.
Daroudi R, Akbari Sari A, Nahvijou A, et al (2015). The 
economic burden of breast cancer in Iran. Iran J Public 
Health, 44, 1225-33.
Eichler HG KS, Gerth WC, Mavros P, Gerth WC, Mavros 
P (2004). Use of cost-effectiveness analysis in health 
care resource allocation decision- making: how are 
cost- effectiveness thresholds expected to emerge?. Value 
Health, 7, 518-28.
Ferlay J, Autier P, Boniol M, et al (2007). Estimates of the cancer 
incidence and mortality in Europe in 2006. Ann Oncol, 18, 
581-92.
Gohari MR, Mahmoudi M, Kazem M, Pasha E, Khodabakhshi 
R (2006). Recurrence in breast cancer analysis with frailty 
model. Saudi Med J, 27, 1187-93.
Hatam N, Dehghani M, Habibian M, Jafari A (2015). Cost-utility 
analysis of IEV drug regimen versus ESHAP drug regimen 
for the patients with relapsed and refractory hodgkin and 
non-hodgkin’s lymphoma in Iran. Iran J Cancer Prev, 8, 
e4061.
International Agency for Research on Cancer, World Health 
Organization. GLOBOCAN 2012: estimated cancer 
incidence, mortality and prevalence worldwide in 2012. 
Available from: http://globocan.iarc.fr/Default.aspx 
Accessed 21 Sept 2015.
Kimman ML, Dirksen CD, Voogd AC , et al (2011). Economic 
evaluation of four follow-up strategies after curative 
treatment for breast cancer: results of an RCT. EJC, 47, 
1175-85.
Kimman ML, Voogd AC, Dirksen CD, et al (2007). Improving 
the quality and efficiency of follow-up after curative 
treatment for breast cancer: rational and study design of 
MaCare trial. BMC Cancer, 7, 1.
Koko R, Hakama M, Holli K (2005). Follow-up cost of 
breast cancer patients with localized disease after primary 
treatment: a randomized trial. Breast Cancer Res Treat, 93, 
255–60.
Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H (2010). 
five common cancers in Iran. Arch Iran Med, 13,143-6.
Lauzier S, Levesque P, Mondor M, et al (2013). Out-of-pocket 
costs in the year after early breast cancer among Canadian 
women and spouses. JNCI, 105, 280-92.
Lu W, Greuter MJ, Schaapveld M, et al (2012). Safety and cost 
effectiveness of shorting hospital follow-up after breast 
cancer treatment. BJS, 99, 1227-33.
Margenthaler JA, Allam E, Chen L, et al (2012). Surveillance of 
patients with the breast cancer after curative-intent primary 
treatment: current practice patterns. J Oncol Prac, 8, 79-83. 
Margenthaler JA, Johnson FE, Cyr AE (2014). Intensity of 
follow-up after breast cancer surgery: low versus high. Ann 
Surg Oncol J, 21, 733-7.
Moschetti I, Cinquini M, Lambertini M, Levaggi A, Liberati A 
(2016). Follow-up strategies for women treated for early 
breast cancer. Cochrane Database Syst Rev, 5, CD001768.
NCCN clinical practice guidelines in oncology. Available 
from:http://www.nccn.org/professionals/physician_gls/f_
guidelines.asp#breast. Accessed 4 Sept 2013.
Oltra A, Santaballa A, Munarriz B, Pastor M, Montalar J (2007). 
Cost-benefit analysis of a follow-up program in patients 
with breast cancer: a randomized prospective study. Breast 
J, 13, 571-4. 
Rosselli Del Turco M, Palli D, Cariddi A, et al (1994). Intensive 
diagnostic follow-up after treatment of primary breast cancer. 
A randomized trial. National research council project on 
breast cancer follow- up. JAMA, 271, 1593–7.
The GIVIO Investigators (1994). Impact of follow-up testing on 
survival and health-related quality of life in breast cancer 
patients. A multicenter randomized controlled trial. JAMA, 
271, 1587–92.
The world bank [online].2016; Available from: http://databank.
worldbank.org/data/reports.aspx?source=2&series=ny.gdp.
pcap.cd&country=irn. Accessed 13 july 2015.
Van hezewijk M, van den akker ME, van de velde CJH, Scholten 
AN, Hille E TM (2012). Costs of different follow-up 
strategies in early breast cancer: a review of the literature. 
Breast J, 21, 693-700.
